Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Centessa Pharmaceuticals plc American Depositary Shares (CNTA)

Pharmaceutical Preparations

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

3RD FLOOR, 1 ASHLEY ROAD
ALTRINCHAM, CHESHIRE, X0

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/28/2021

Market Cap

1,418,683,272

Shares Outstanding

97,630,000

Weighted SO

97,629,345

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

IPSC --.--%

EWTX --.--%

CCCC --.--%

MLYS --.--%

MLYS --.--%

CGEM --.--%

CGEM --.--%

NAMSW --.--%

NAMSW --.--%

Beta

1.4090

Last Div

0.0000

Range

5.15-13.557

Chg

-0.5550

Avg Vol

269150

Mkt Cap

1418683272

Exch

NASDAQ

Country

GB

Phone

44 203 9206789

DCF Diff

11.8190

DCF

0.9210

Div Yield

0.0000

P/S

205.2311

EV Multiple

-8.9673

P/FV

4.7826

Div Yield %

0.0000

P/E

-8.7032

PEG

-0.2754

Payout

0.0000

Current Ratio

13.2873

Quick Ratio

13.2873

Cash Ratio

4.7607

DSO

2481.3254

DIO

0.0000

Op Cycle

2481.3254

DPO

2020.8492

CCC

460.4763

Gross Margin

0.8610

Op Margin

-22.5373

Pretax Margin

-22.8829

Net Margin

-22.8126

Eff Tax Rate

0.0031

ROA

-0.3954

ROE

-0.6322

ROCE

-0.4187

NI/EBT

0.9969

EBT/EBIT

1.0153

EBIT/Rev

-22.5373

Debt Ratio

0.1932

D/E

0.2685

LT Debt/Cap

0.2105

Total Debt/Cap

0.2117

Int Coverage

-30.4578

CF/Debt

-1.9444

Equity Multi

1.3899

Rec Turnover

0.1471

Pay Turnover

0.1806

Inv Turnover

0.0000

FA Turnover

0.5586

Asset Turnover

0.0173

OCF/Share

-1.3683

FCF/Share

-1.3691

Cash/Share

2.6928

OCF/Sales

-21.6733

FCF/OCF

1.0005

CF Coverage

-1.9444

ST Coverage

-271.4116

CapEx Coverage

-1848.8896

Div&CapEx Cov

-1848.8896

P/BV

4.7826

P/B

4.7826

P/S

205.2311

P/E

-8.7032

P/FCF

-9.4642

P/OCF

-9.1607

P/CF

-9.1607

PEG

-0.2754

P/S

205.2311

EV Multiple

-8.9673

P/FV

4.7826

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Sep 13, 02:34 Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares Zacks Investment Research Dec 26, 09:29 What Awaits These 4 Drug Stocks That More Than Doubled in 2023? GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia GlobeNewswire Inc. Dec 10, 12:05 Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

Revenue Product Segmentation